Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Por um escritor misterioso
Descrição
Deciding between one-step and two-step irreversible inhibition mechanisms on the basis of “kobs” data: A statistical approach
Kinetic mechanisms of covalent inhibition - ScienceDirect
Deciding between one-step and two-step irreversible inhibition mechanisms on the basis of “kobs” data: A statistical approach
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two – topic of research paper in Biological sciences. Download scholarly article PDF and read for
Full article: Drug delivery targets and strategies to address mast cell diseases
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors
Kinetic mechanisms of covalent inhibition - ScienceDirect
Frontiers Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies, Journal of Hematology & Oncology
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. - Abstract - Europe PMC
Pharmaceuticals, Free Full-Text
Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen
Case Study - COVALfinder to Study Irreversible EGFR Drugs
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies, Journal of Hematology & Oncology
A Perspective on the Kinetics of Covalent and Irreversible Inhibition
